HBZ is an immunogenic protein, but not a target antigen for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes
HBZ is an immunogenic protein, but not a target antigen for human T-cell leukemia virus type 1-specific cytotoxic T lymphocytes
复制标题
DOI：
10.1099/vir.0.010199-0
复制
发表时间：
2009-08-01
影响因子：
3.8
通讯作者：
Yasukawa, Masaki
中科院分区：
文献类型：
--
作者：
Suemori, Koichiro;Fujiwara, Hiroshi;Yasukawa, Masaki
最近，HBZ被报道在成人T细胞白血病(ATL)细胞的增殖中发挥重要作用，并可能成为ATL新的治疗靶点。为了开发一种新的ATL免疫治疗方法，我们验证了针对HBZ的细胞免疫治疗的可行性。我们建立了HBZ特异性和人类白细胞抗原-A*0201限制性的细胞毒性T淋巴细胞(CTL)克隆。使用该CTL克隆的详细研究清楚地表明，HBZ确实是一种可被人CTL识别的免疫原性蛋白；然而，HBZ特异性CTL不能溶解ATL细胞。HBZ特异性CTL不能识别人类T细胞白血病病毒1型(HTLV-1)感染的细胞可能是由于HBZ蛋白在ATL细胞中的低水平表达以及HTLV-1感染的细胞对CTL介导的细胞毒产生抵抗力所致。虽然HBZ在HTLV-1感染细胞的增殖中起着重要作用，但它也可能提供一种新的机制，使它们能够逃避免疫识别。
Recently, HBZ has been reported to play an important role in the proliferation of adult T-cell leukaemia (ATL) cells and might be a target of novel therapy for ATL. To develop a novel immunotherapy for ATL, we verified the feasibility of cellular immunotherapy targeting HBZ. We established an HBZ-specific and HLA-A*0201-restricted cytotoxic T lymphocyte (CTL) clone. Detailed study using this CTL clone clearly showed that HBZ is certainly an immunogenic protein recognizable by human CTLs; however, HBZ-specific CTLs could not lyse ATL cells. Failure of HBZ-specific CTLs to recognize human T-cell leukemia virus type 1 (HTLV-1)-infected cells might be due to a low level of HBZ protein expression in ATL cells and resistance of HTLV-1 -infected cells to CTL-mediated cytotoxicity. Although HBZ plays an important role in the proliferation of HTLV-1 infected cells, it may also provide a novel mechanism that allows them to evade immune recognition.